CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas (FCM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Professor Sposito holds a degree in Medicine from the Federal University of Bahia (1992) and completed his residency in Internal Medicine and Cardiology in the Faculty of Medicine of the University of São Paulo (USP) (1993-1996). He obtained his Doctorate in Medicine from the Faculty of Medicine of USP, São Paulo (1996-1999) and he pursued postdoctoral studies at the University of Paris-Sorbonne, Paris, France (2000-2003), with a research stint at the Children's Cell Biology Laboratory at the Hospital of Philadelphia, Pennsylvania, USA. In 2008, he was awarded Professor Habilitation in Cardiology at the University of São Paulo School of Medicine. He held various prestigious positions in the field of cardiology, including Editor of the Brazilian Guideline for the Prevention of Atherosclerosis (2007), President of the Department of Atherosclerosis (2008-2009), and Scientific Director of the Midwest Regional (2010-2011) of the Brazilian Society of Cardiology. Furthermore, he served as Director of Research (2012-2013) and Director of the Regionals (2022-2023) for the São Paulo State Cardiology Society. Prof. Sposito holds the position of full professor (MS-6) in the Cardiology discipline at the Faculty of Medical Sciences of Unicamp. He also serves as a member of the Advisory Board for prestigious journals such as Ebiomedicine (Lancet), atherosclerosis, and the Journal of Geriatric Cardiology. Additionally, he has acted as a section editor for the BBA Clinical section. Dr. Sposito has made significant contributions to the field of cardiology, including authoring chapters in renowned medical textbooks such as Harrison's Principles of Internal Medicine and Braunwald's Heart Disease. Moreover, his research has been published in leading journals specializing in Internal Medicine and Cardiology. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The use of Sglt2 inhibitors (Sglt2i) in patients with moderate chronic kidney disease (CKD) demonstrated a reduction of up to 29% in the incidence of cardiovascular death and hospitalization for heart failure (HF). In addition to the effect of this class on natriuresis, experimental data suggest the action of Sglt2i directly on the myocardium. This cardiovascular benefit does not attenuat…
Acute and chronic coronary artery diseases are leading causes of deaths worldwide, demanding new advanced healthcare strategies to mitigate this risk, including the development of materials and inter/trans-disciplinary approaches to treat coronary artery occlusion or stenosis. Hence, the main aim of this project is the development of new polymeric biomaterials for applications in the fiel…
Obesity affects more than 400 million subjects in the world and projections for the next 15 years predict an overall prevalence of up to 20%. In developing countries, such as Brazil a rapid nutritional transition provided by the recent economical growth has led to a unique condition on which the malnourished persist in parallel with an increasing number of obese subjects. It is expected t…
Since its report by the World Health Organization in February 2020, SARS-CoV-2 has spread rapidly at an alarming rate, becoming a pandemic on March 12, 2020. In early April, more than 1 million cases were reported. confirmed and there are no signs of slowdown in transmission. Brazil, with more than 10,000 cases as of the beginning of April 2020, is the most affected country in Latin Ameri…
Acute myocardial infarction (AMI) is the leading cause of death worldwide. Coronary reperfusion is the most effective therapy in this scenario, aimed at preserving the left ventricular ejection fraction and improving clinical outcomes in patients with AMI. Paradoxically, however, such a strategy leads to a deleterious phenomenon called ischemia reperfusion injury (IRI), which induces addi…
Background: Misclassification of patients as low cardiovascular risk (LCR) remains a major concern and challenges the efficacy of traditional risk markers. Due to its strong association with cholesterol acceptor capacity, high-density lipoprotein (HDL) size has been appointed as a potential risk marker. Hence, we investigate whether HDL size improves the predictive value of HDL-cholestero…
(Only some records are available in English at this moment)
Introduction: One of the biggest health challenges in the world is to reduce cardiovascular complications in patients with chronic kidney disease. Recent evidence has shown that gliflozins are associated with a reduced risk of death from cardiovascular causes in diabetic individuals. The potential extent of this benefit to dialysis patients is limited by the lack of safety studies for thi…
Type 2 diabetes mellitus is a disorder of glucose metabolism, a clinical, progressive syndrome whose main mechanism is insulin resistance. For the next two decades, there is a prospect that almost 700 million individuals will be affected by DM2. Patients with DM2 have up to 3x higher cardiovascular mortality compared to healthy individuals. And, due to its pathophysiological mechanisms, D…
In patients with type 2 diabetes (T2DM), declining glomerular filtration rate (GFR) and progression of proteinuria are defining elements of diabetic nephropathy (DN). In relation to patients with DM2 without renal involvement, individuals with DN have a mortality rate up to 2 times higher, and an increased risk up to 5 times of developing chronic kidney disease requiring renal replacement…
(Only some records are available in English at this moment)
| 3 / 3 | Ongoing grants |
| 4 / 4 | Completed research grants |
| 16 / 16 | Completed scholarships in Brazil |
| 23 / 23 | All research grants and scholarships |
| Associated processes | |